Literature DB >> 33034031

Notch Signaling in Thyroid Cancer.

Rachael Guenter1, Zeelu Patel1, Herbert Chen2.   

Abstract

Thyroid cancer is the most common malignancy of the endocrine system with a steadily rising incidence. The term "thyroid cancer" encompasses a spectrum of subtypes, namely papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, and medullary thyroid cancer. Each subtype differs histopathologically and in degrees of cellular differentiation, which may be in part due to signaling of the Notch pathway. The Notch pathway is an evolutionarily conserved signal transduction mechanism that regulates cell proliferation, differentiation, survival, stem cell maintenance, embryonic and adult development, epithelial-mesenchymal transition, and angiogenesis. Its role in cancer biology is controversial, as it has been shown to play both an oncogenic and tumor-suppressive role in many different types of cancers. This discordance holds true for each subtype of thyroid cancer, indicating that Notch signaling is likely cell type and context dependent. Whether oncogenic or not, Notch signaling has proven to be significantly involved in the tumorigenesis of thyroid cancer and has thus earned interest as a therapeutic target. Advancement in the understanding of Notch signaling in thyroid cancer holds great promise for the development of novel treatment strategies to benefit patients.

Entities:  

Keywords:  Anaplastic thyroid cancer; Follicular thyroid cancer; HDAC inhibitors; Medullary thyroid cancer; Notch pathway; Notch signaling; Notch signaling modulation; Papillary thyroid cancer; Thyroid cancer

Mesh:

Substances:

Year:  2021        PMID: 33034031      PMCID: PMC8422843          DOI: 10.1007/978-3-030-55031-8_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  95 in total

1.  Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies.

Authors:  Patrick A Zweidler-McKay; Yiping He; Lanwei Xu; Carlos G Rodriguez; Fredrick G Karnell; Andrea C Carpenter; Jon C Aster; David Allman; Warren S Pear
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

2.  Character Changes Caused by Mutation of an Entire Region of a Chromosome in Drosophila.

Authors:  O L Mohr
Journal:  Genetics       Date:  1919-05       Impact factor: 4.562

3.  Expression of the active Notch1 decreases MTC tumor growth in vivo.

Authors:  Renata Jaskula-Sztul; Pongthep Pisarnturakit; Michael Landowski; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  J Surg Res       Date:  2011-04-13       Impact factor: 2.192

Review 4.  Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?

Authors:  Christos Damaskos; Nikolaos Garmpis; Serena Valsami; Eleftherios Spartalis; Efstathios A Antoniou; Periklis Tomos; Stefanos Karamaroudis; Theofano Zoumpou; Vasilios Pergialiotis; Konstantinos Stergios; Constantinos Michaelides; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

Review 5.  Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.

Authors:  T Kogai; K Taki; G A Brent
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

6.  Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis.

Authors:  Yash R Somnay; Xiao-Min Yu; Ricardo V Lloyd; Glen Leverson; Zviadi Aburjania; Samuel Jang; Renata Jaskula-Sztul; Herbert Chen
Journal:  Cancer       Date:  2016-11-02       Impact factor: 6.860

7.  Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.

Authors:  C Schmutzler; R Winzer; J Meissner-Weigl; J Köhrle
Journal:  Biochem Biophys Res Commun       Date:  1997-11-26       Impact factor: 3.575

8.  Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

Authors:  Jennifer A Woyach; Richard T Kloos; Matthew D Ringel; Daria Arbogast; Minden Collamore; James A Zwiebel; Michael Grever; Miguel Villalona-Calero; Manisha H Shah
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

9.  Follicular thyroid carcinomas with lung metastases: a 23-year retrospective study.

Authors:  Jen-Der Lin; Tzu-Chieh Chao; Chuen Hsueh
Journal:  Endocr J       Date:  2004-04       Impact factor: 2.349

Review 10.  Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.

Authors:  Camille Lobry; Philmo Oh; Iannis Aifantis
Journal:  J Exp Med       Date:  2011-09-26       Impact factor: 14.307

View more
  3 in total

1.  Global research hotspots and trends of the Notch signaling pathway in the field of cancer: a bibliometric study.

Authors:  Kunyang Lei; Xu Wang; Yifu Liu; Ting Sun; Wenjie Xie
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  Analysis of the Mechanism of Maslinic Acid on Papillary Thyroid Carcinoma Based on RNA-Seq Technology.

Authors:  Rong Li; Yanjiao Zhang; Runqing Xiang; Aihe Lin; Zongxiao Xia; Xiaomei Long; Shuang Guo; Yuan Fan; Zukun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-07       Impact factor: 2.650

Review 3.  Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective.

Authors:  Abdellah Akil; Ana K Gutiérrez-García; Rachael Guenter; J Bart Rose; Adam W Beck; Herbert Chen; Bin Ren
Journal:  Front Cell Dev Biol       Date:  2021-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.